Announcement: UEDA Heart Awards for 2018

Area of Science:

• Cardiology
• Biomedical Engineering
• Pharmacology

Background:

• Severe mitral regurgitation and acute myocardial infarction are significant causes of heart failure.
• Right ventricular dysfunction and diabetes mellitus are critical factors influencing heart failure outcomes.
• Left ventricular remodeling after myocardial infarction contributes to long-term morbidity and mortality.

Purpose of the Study:

• To investigate the role of right ventricular dysfunction and diabetes mellitus in N-terminal pro-B-type natriuretic peptide response in patients with severe mitral regurgitation and heart failure.
• To evaluate the efficacy of nanoparticle-mediated pitavastatin delivery to monocytes/macrophages in inhibiting left ventricular remodeling after acute myocardial infarction.

Main Methods:

• Analysis of N-terminal pro-B-type natriuretic peptide levels in patients with severe mitral regurgitation and heart failure, considering right ventricular function and diabetes status.
• Utilizing nanoparticle drug delivery systems to target monocytes/macrophages for pitavastatin administration in a preclinical model of acute myocardial infarction.

Main Results:

• First Place: Right ventricular dysfunction and diabetes mellitus significantly impact N-terminal pro-B-type natriuretic peptide response in patients with severe mitral regurgitation and heart failure.
• Second Place: Nanoparticle-mediated pitavastatin delivery effectively inhibited monocyte-mediated inflammation, leading to reduced left ventricular remodeling post-myocardial infarction.

Conclusions:

• Understanding the interplay of right ventricular dysfunction and diabetes is crucial for managing heart failure in severe mitral regurgitation.
• Targeted nanoparticle delivery of pitavastatin offers a promising therapeutic strategy to mitigate adverse left ventricular remodeling and inflammation after myocardial infarction.